News

The USFDA decision provides a regulatory basis for further steps, including WHO pre-qualification and national regulatory approvals

The USFDA decision provides a regulatory basis for further steps, including WHO pre-qualification and national regulatory approvals

The company’s Srikakulam unit has received USFDA’s VAI classification

The USFDA had conducted PAI and GMP inspection at the company’s said unit in Andhra Pradesh

Consolidated total income of the company declined by 3.26% to Rs 8,854.00 crore in Q2FY27

The company entered into a licensing and commercialization agreement with Junshi Biosciences in 2023 for toripalimab across 21 countries

The company has been issued a Form 483 with three observations

The launch of NIVORZ further strengthens the company’s oncology portfolio and expands its presence in immuno-oncology

The inspection was conducted from August 6, 2026 to August 14, 2026

The approval further strengthens its growing global biosimilars portfolio and advances its biosimilars business in the United States

The approval further strengthens its growing global biosimilars portfolio and advances its biosimilars business in the United States

Consolidated total income of the company declined by 4.60% to Rs 8,454.50 crore in Q1FY27

Consolidated total income of the company declined by 4.60% to Rs 8,454.50 crore in Q1FY27

Dr. Reddy’s has collaborated with MSN Laboratories on this product

The company’s Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus

Consolidated total income of the company decreased by 11.37% at Rs 8,021.80 crore for Q4FY26

The company becomes the first company to receive the market authorization for generic Semaglutide Injection in Canada

Consequent to the completion of the transaction, Svaas Wellness will cease to be a wholly owned subsidiary of the Company

The company has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide

USFDA has classified the inspection outcome as Voluntary Action Indicated

The acquisition strengthens Dr. Reddy’s gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment

The acquisition strengthens Dr. Reddy’s gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment

The company has reported 14% fall in Q3 consolidated net profit

Consolidated total income increased by 5.75% at Rs 9,022.20 crore for Q3FY26

The company’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is available in a 2.5 mL bottle

The company’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is available in a 2.5 mL bottle

The USFDA conducted a GMP and a Pre-Approval Inspection (PAI) of the said facility

Dr. Reddy’s Laboratories SA has entered into a strategic collaboration and exclusive Licensing agreement with Immutep SAS

In May 2024, Dr. Reddy’s Laboratories and Alvotech entered into a license and supply agreement for the commercialization of AVT03

The consolidated total income of the company increased by 9.66% at Rs 9152.20 crore for Q2FY26

USFDA has classified the inspection outcome as Voluntary Action Indicated

The company initiated the nationwide (US) Class II recall on September 26 this year

Tegoprazan is a next-generation potassium-competitive acid blocker

The inspection was conducted from September 4, 2025 to September 12, 2025`

The said acquisition will strengthen Dr. Reddy’s Central Nervous System Portfolio in India and Emerging Markets through its foray into the antivertigo segment

The USFDA has classified the inspection outcome as Voluntary Action Indicated

The USFDA has classified the inspection outcome as Voluntary Action Indicated

The fund infused by the company into DRL Russia will be used for working capital requirements

Total consolidated income of the company increased by 12.41% at Rs 8862.40 crore for Q1FY26

Total consolidated income of the company increased by 12.41% at Rs 8862.40 crore for Q1FY26

The USFDA has classified the inspection outcome as Voluntary Action Indicated

The inspection was conducted from July 10, 2025 to July 18, 2025

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities

The inspection was conducted from May 19, 2025 to May 24, 2025

The inspection was conducted from May 12, 2025 to May 16, 2025

The total consolidated income of the company increased by 23.79% at Rs 9,050.50 crore for Q4FY25

The medication is also administered in children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season

The company has issued the Class 1 nationwide (US) recall on March 13, 2025

Dr. Reddy’s will be responsible for seeking regulatory approvals as well as commercialization in the licensed territories

Dr. Reddy’s Laboratories Louisiana has ceased to be a wholly owned subsidiary of Dr. Reddy’s Laboratories Inc. and a step-down wholly owned subsidiary of Dr. Reddy’s Laboratories

The USFDA has classified the inspection as VAI and concluded that the inspection is ‘closed’ under 21 CFR 20.64(d)(3)

The USFDA has classified the inspection as VAI and concluded that the inspection is ‘closed’ under 21 CFR 20.64(d)(3)

Total income of the company increased by 14.47% at Rs 8531.40 crore for Q3FY25

The company’s arm has entered into an agreement to sell membership interests in DRLL

Consequently, Dr. Reddy’s Laboratories Louisiana LLC will cease to be a wholly owned subsidiary of Dr. Reddy’s Laboratories Inc

Dr. Reddy’s Finland Oy is a step-down wholly-owned subsidiary of the company

Dr. Reddy’s Finland Oy is a step-down wholly-owned subsidiary of the company

The company launched Toripalimab in India

It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, EMA, MHRA, and others for the treatment of adults with RM-NPC

Dr. Reddy’s Laboratories’ US-based subsidiary is recalling 2,040 bottles of 15 mg Morphine Sulfate extended-release tablets

Dr Reddy’s Laboratories Inc is also recalling another 532 100-count bottles of the medication in 30 mg strength for the same reason

The fund will be used for working capital requirements

Total consolidated income of the company increased by 15.63% at Rs 8345.70 crore for Q2FY25

Total consolidated income of the company increased by 15.63% at Rs 8345.70 crore for Q2FY25

Dr Reddy’s is the first company to receive approval for and launch such a drug (Elobixibat) in India

Accordingly, Dr. Reddy’s Denmark ApS is a step-down wholly-owned subsidiary of the company

Accordingly, Dr. Reddy’s Denmark ApS is a step-down wholly-owned subsidiary of the company

The agreement is for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other countries

The agreement is for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other countries

DRL SA has allotted 6,200,000 non-convertible preference shares each with a nominal value of $100 to the company on September 27, 2024

The inspection closed with zero observations

Consequently, Dr. Reddy’s Venezuela C.A. will cease to be a wholly owned subsidiary of Dr. Reddy’s Swiss as well as step down wholly owned subsidiary of the Company

The launch marks the company’s entry into digital therapeutics in Europe

Vericiguat works on a pathway not currently targeted by existing heart failure treatments and can reduce the combined risk of cardiovascular death and heart failure hospitalization in such patient

The company has entered into an exclusive partnership to promote and distribute their vaccine brands across private markets in India

The company has entered into an exclusive partnership to promote and distribute their vaccine brands across private markets in India

As per the agreement, Dr. Reddy’s has received exclusive rights to market and distribute Centhaquine in India

Versavo is the first Dr. Reddy’s biosimilar product to be approved and launched in the UK

The certificate of incorporation has been issued by the Ministry of Corporate Affairs, Government of India, on March 14, 2024

The company has received Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA)

Bharat Forge has infused funds in Bharat Forge America Inc., a wholly owned subsidiary of the Company on February 09, 2024

The USFDA has classified the inspection as Voluntary Action Indicated and concluded that the inspection is ‘closed’ under 21 CFR 20.64(d)(3)

Total consolidated income of the company increased by 8.83% at Rs 7453.00 crore for Q3FY24

Total consolidated income of the company increased by 8.83% at Rs 7453.00 crore for Q3FY24

The affected lot was produced at Dr Reddy’s Bachupally-based plant near Hyderabad

The company acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause

The funds invested by the company would be utilized by Edity to further develop its technology platform

The funds invested by the company would be utilized by Edity to further develop its technology platform

The inspection was conducted from December 4, 2023 to December 8, 2023

Under the terms of the Agreement, Coya has granted Dr. Reddy’s an exclusive license to commercialize COYA 302

Under the terms of the Agreement, Coya has granted Dr. Reddy’s an exclusive license to commercialize COYA 302

The product is indicated to prevent wheezing, breathing difficulty, chest tightness, and coughing caused by asthma in adults

The product is indicated to prevent wheezing, breathing difficulty, chest tightness, and coughing caused by asthma in adults

Nerivio can be worn on the upper arm

Nerivio can be worn on the upper arm

The object of acquisition is to access renewable power through solar and wind power plants through ISTS under captive structure

Alok Industries has entered into facility agreements with Axis Bank for availing a term loan of Rs 1750 crore

The object of acquisition is to access renewable power through solar and wind power plants through ISTS under captive structure

USFDA has issued a Form 483 with ten observations

Total consolidated income of the company increased by 13.26% at Rs 7217.60 crore for Q2FY24

The company has been issued a Form 483 with nine observations

Dr. Reddy’s Laboratories Jamaica is a step-down wholly-owned subsidiary of the company

Dr. Reddy’s Laboratories Jamaica is a step-down wholly-owned subsidiary of the company

The Board of Directors of the Company at its meeting held on September 28, 2023, has approved the same

Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30

Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30

Total consolidated income of the company increased by 13.88% at Rs 6931.90 crore for Q1FY24

Total consolidated income of the company increased by 13.88% at Rs 6931.90 crore for Q1FY24

The inspection closed with zero observations and a classification of No Action Indicated

Orient Tradelink has signed mega deal with Zee5 and initiated syndication of content to National and International buyers

The company has entered into a Security Subscription and Shareholders’ agreement with TEQ Green Power XI and O2 Power SG Pte

This closely follows acceptance of its rituximab biosimilar dossier for review by two other regulatory agencies-EMA and the United Kingdom’s MHRA

The company aims to get into integrated digital healthcare services as part of its future growth plans

The company aims to get into integrated digital healthcare services as part of its future growth plans

As part of the collaboration, the company has migrated its SAP platform entirely onto AWS

CeleHealth Kidz Immuno Plus Gummies aim to address the nutritional requirements due to the growing issues around child immunity in India

CeleHealth Kidz Immuno Plus Gummies aim to address the nutritional requirements due to the growing issues around child immunity in India

The new business will further the company’s goal of reaching over 1.5 billion patients by 2030

The new business will further the company’s goal of reaching over 1.5 billion patients by 2030

The inspection closed with zero observations

The inspection was conducted from May 8, 2023 to May 12, 2023

Monte Carlo Fashions has made further investment to the extent of Rs 5 crore in Monte Carlo Home Textiles

The inspection was conducted from May 1, 2023 to May 5, 2023

The company’s Regadenoson Injection is supplied as single-dose pre-filled syringes

The company’s Treprostinil Injection is supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials

As per IQVIA MAT December 2022, the divested portfolio saw sales of Rs 60 crore in India

The affected lot was produced at the company’s Bachupally-based manufacturing plant

The acquisition will complement Dr. Reddy’s U.S. retail prescription pharmaceutical business with limited competition products

The 2023 index includes 484 companies representing 11 sectors, 45 countries and a market capitalization of $16 trillion

Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24

Total consolidated income of the company increased 26.96% at Rs 6848.50 crore for Q3FY23

Total consolidated income of the company increased 26.96% at Rs 6848.50 crore for Q3FY23

The company’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets

This price reduction will further widen access to this trusted and established brand

Since May 2022, the company has been marketing the drug in collaboration with Pfizer Products India under the brand name PRIMCYV in India

Nerivio is a wearable migraine treatment that stimulates the body’s pain receptors in order to relieve acute and chronic migraine pain

The company’s Tocilizumab biosimilar candidate ’DRL_TC’ successfully met its primary and secondary endpoints in a Phase 1 study

The agreed consideration for the assets and liabilities of the said site is Euro 1

Aurigene will be closing the clinical development of AUR101 in psoriasis`

According to USFDA, the company is recalling the affected lot due to ‘failed stability specifications’

The company also plans to utilise the capital for adding capacities to existing plants, firm up R&D activities and further invest in digitisation projects

Total consolidated income of the company increased by 6.34% at Rs 6372.60 crore for Q2FY23

According to the USFDA, the company is recalling the affected lot due to failed stability specifications

With this recognition, the facility joins the GLN

With this volume-limited launch, Dr. Reddy’s is eligible for first-to market, 180 days of generic drug exclusivity for Lenalidomide Capsules

The agency has concluded that the inspection is ‘closed’

Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis

The New Jersey-based firm initiated the Class II nationwide recall on July 13

Allegra-D 24 HR had U.S. retail sales of approximately $45 million as of May 2022 according to IRI

Tata Motors has hiked prices of its passenger vehicles

Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30

The inspection was conducted from June 30, 2022 to July 07, 2022

Besides, by 2030 the company will use 100 per cent renewable power and it will also be carbon-neutral in direct emissions

The partnership aims to accelerate the development of drugs candidates in the area of oncology

Dr. Reddy’s Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120

Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for rights to a pre-existing Aurigene program

Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for rights to a pre-existing Aurigene program

The company’s Pemetrexed for Injection, is supplied in 100 mg and 500 mg single-dose vials

Dr. Reddy’s Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100

Infosys is reportedly shifting its services from Russia to its other global delivery centres